27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

Key Takeaways Explain This Topic AI

The modern definition of TIA is tissue-based: a transient episode of focal neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction on diffusion-weighted MRI; symptom resolution within 24 hours does NOT constitute a TIA if acute infarction is radiographically evident.

The ABCD2 score stratifies 48-hour stroke risk following TIA: Age ≥60 (1 pt), Blood pressure ≥140/90 (1 pt), Clinical features (unilateral weakness [2 pts] or speech disturbance alone [1 pt]), Duration (≥60 min [2 pts] or 10-59 min [1 pt]), and Diabetes (1 pt); a score ≥4 indicates moderate-to-high risk (4.1% to 8.1% at 48 hours) requiring urgent hospital admission.

Urgent diagnostic workup within 24-48 hours requires brain MRI with diffusion-weighted imaging (DWI), neurovascular imaging (CTA, MRA, or carotid ultrasound), and cardiac telemetry/monitoring to detect paroxysmal atrial fibrillation; symptomatic carotid stenosis of 70-99% requires urgent carotid endarterectomy (CEA) within 14 days.

Dual Antiplatelet Therapy (DAPT) with Aspirin 81 mg daily PLUS Clopidogrel 75 mg daily (with a 300-600 mg load) is indicated for high-risk TIA (ABCD2 ≥4) or minor ischemic stroke (NIHSS ≤3) for exactly 21 days (CHANCE and POINT trials), transitioning to lifelong monotherapy to minimize major bleeding.

Non-cardioembolic TIA mandates high-intensity statin therapy (atorvastatin 80 mg daily) targeting LDL <70 mg/dL (or ≥50% reduction), alongside blood pressure optimization (<130/80 mmHg); if atrial fibrillation is detected, oral anticoagulation (DOAC) is indicated and supersedes antiplatelet therapy.

Last updated: September 2026

Transient Ischemic Attack (TIA): The Modern Tissue-Based Definition & Pathophysiology

Transient Ischemic Attack (TIA) is a medical emergency that serves as a critical harbinger of impending cerebral infarction. Approximately 10% to 15% of patients who experience a TIA will suffer a completed ischemic stroke within 90 days, with half of those strokes occurring within the first 48 hours following the index event. Prompt recognition, rapid risk stratification, and emergent secondary prevention dramatically reduce this risk by up to 80%.

The Shift: Time-Based vs. Tissue-Based Definitions

For decades, the World Health Organization defined TIA using an arbitrary time-based definition : a sudden focal neurological deficit of presumed vascular etiology that resolved completely within 24 hours. Advances in neuroimaging have rendered this definition obsolete.

The Modern Tissue-Based Definition (AHA/ASA) : "A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction."

The Biological Rationale :

Diffusion-Weighted Imaging (DWI) on Magnetic Resonance Imaging (MRI) is exquisitely sensitive to acute cytotoxic edema. High-resolution MRI reveals that up to 30% to 50% of patients whose clinical symptoms resolve completely in <24 hours have distinct focal hyperintensities on DWI , representing true microscopic ischemic cerebral infarction. Under contemporary guidelines, any patient with objective radiographic evidence of acute infarction is classified as having suffered an Ischemic Stroke (Cerebral Infarction) , regardless of whether their symptoms lasted 15 minutes or 2 hours. The diagnosis of true TIA is reserved strictly for patients with transient focal ischemic symptoms AND a completely normal DWI-MRI . TRADITIONAL vs CONTEMPORARY TIA DEFINITION

• TRADITIONAL (TIME-BASED) CONTEMPORARY (TISSUE-BASED)
• ──────────────────────────────────────────────────────────────────────────
• Symptoms resolve in < 24 hours • Symptoms transient (focal ischemia)
• Neuroimaging status ignored • MANDATORY: No evidence of acute
• Masks micro-infarctions as benign infarction on Diffusion-Weighted MRI
• Obsolete in modern guidelines • DWI positive = ISCHEMIC STROKE
• DWI negative = TRUE TIA
• Vascular Territories & Clinical Phenotypes

TIAs produce sudden-onset, focal "negative" deficits corresponding to discrete arterial territories:

Anterior Circulation (Carotid / Middle Cerebral / Anterior Cerebral Arteries) :

Middle Cerebral Artery (MCA) : Unilateral motor weakness (face and arm > leg), unilateral sensory loss, expressive dysphasia (Broca's) or receptive aphasia (Wernicke's) in dominant hemisphere, or hemispatial neglect in non-dominant hemisphere;

Anterior Cerebral Artery (ACA) : Contralateral lower extremity weakness and sensory loss (leg > arm), abulia, gait apraxia, or urinary incontinence;

Ophthalmic / Retinal Artery : Amaurosis Fugax (transient monocular vision loss): Sudden, painless loss of vision in one eye, characteristically described as a "black shade or curtain descending over the visual field," lasting 2 to 15 minutes, caused by temporary microembolization of retinal arterioles from an ipsilateral carotid atheroma.

Posterior Circulation (Vertebrobasilar / Posterior Cerebral Arteries) :

Posterior Cerebral Artery (PCA) : Contralateral homonymous hemianopia with macular sparing, visual agnosia;

Vertebrobasilar System : Vertigo, ataxia, dysarthria, diplopia, dysphagia, or bilateral limb weakness. Clinical Pearl : Isolated lightheadedness, syncope, or dizziness without other brainstem/cerebellar signs is rarely attributable to a posterior circulation TIA.

The ABCD2 Clinical Prediction Score

The ABCD2 score is a validated clinical prediction tool developed to quantify the short-term risk of recurrent stroke within 48 hours following a suspected TIA. It guides decisions regarding emergency hospitalization, monitoring, and urgent intervention.

Scoring Components & Point Allocation THE ABCD2 SCORING SYSTEM

• CRITERION CLINICAL PARAMETER POINTS
• ──────────────────────────────────────────────────────────────────────────
• A - Age Age ≥ 60 years 1
• ──────────────────────────────────────────────────────────────────────────
• B - Blood Pressure Initial Systolic BP ≥ 140 mmHg 1
• OR Initial Diastolic BP ≥ 90 mmHg
• ──────────────────────────────────────────────────────────────────────────
• C - Clinical Features Unilateral motor weakness (with or without 2
• speech disturbance)
• Speech disturbance WITHOUT unilateral weakness 1
• Other symptoms (e.g., isolated sensory) 0
• ──────────────────────────────────────────────────────────────────────────
• D - Duration Symptom duration ≥ 60 minutes 2
• Symptom duration 10 to 59 minutes 1
• Symptom duration < 10 minutes 0
• ──────────────────────────────────────────────────────────────────────────
• D - Diabetes Pre-existing history of Diabetes Mellitus 1
• ──────────────────────────────────────────────────────────────────────────
• TOTAL SCORE: 0 to 7 points
• Risk Stratification & Predicted Stroke Probability

• Total Score Risk Category 48-Hour Stroke Risk 7-Day Stroke Risk 90-Day Stroke Risk Recommended Disposition
• 0 to 3 Low Risk 1.0% 1.2% 3.1% Outpatient workup acceptable ONLY if completed within 24-48h
• 4 to 5 Moderate Risk 4.1% 5.9% 9.8% Urgent Hospital Admission / Dedicated TIA Unit
• 6 to 7 High Risk 8.1% 11.7% 17.8% Immediate Emergent Hospital Admission / Telemetry
• Criteria for Urgent Hospital Admission

Current AHA/ASA guidelines strongly recommend hospital admission (or placement in a specialized rapid-access TIA observation unit) for patients presenting with suspected TIA within 72 hours if they meet ANY of the following:

ABCD2 score ≥ 4 (moderate to high 48-hour stroke risk);

ABCD2 score 0 to 3 if the mandatory diagnostic workup cannot be guaranteed and completed within 24 to 48 hours in the outpatient setting;

• Crescendo TIAs (two or more distinct focal episodes occurring within a 72-hour window);
• Objective evidence of acute focal brain ischemia on neuroimaging (DWI-positive);
• Known or newly identified symptomatic carotid stenosis ≥50% ;

Documented high-risk cardioembolic source (e.g., atrial fibrillation, left ventricular thrombus, acute myocardial infarction, or severe cardiomyopathy).

Urgent Diagnostic Evaluation Algorithm (Within 24 to 48 Hours)

Every patient presenting with a suspected TIA must undergo a rapid, comprehensive diagnostic evaluation within 24 to 48 hours to identify the underlying etiology (large artery atherosclerosis, cardioembolism, small vessel lacunar disease, or rare etiologies) and initiate targeted secondary prevention. URGENT TIA DIAGNOSTIC PARADIGM

• 1. BRAIN PARENCHYMA IMAGING
• FIRST-LINE: Brain MRI with Diffusion-Weighted Imaging (DWI)
• *80-90% sensitive for micro-infarctions; detects cytotoxic edema*
• ALTERNATIVE: Non-contrast Head CT (if MRI contraindicated or unavailable)
• *Rules out intracranial hemorrhage, subdural hematoma, mass*

• 2. NEUROVASCULAR VESSEL IMAGING (Extracranial & Intracranial)
• Modalities: CT Angiography (CTA) of Head/Neck, MRA, or Carotid Duplex US
• Goal: Identify symptomatic internal carotid artery (ICA) stenosis
• Symptomatic ICA Stenosis 70-99%: URGENT Carotid Endarterectomy (CEA)
• within 14 days of symptom onset (ideally within 48-72 hours)

• 3. CARDIAC EVALUATION
• 12-Lead Electrocardiogram (ECG): Immediate screen for atrial fibrillation/flutter
• Inpatient Continuous Telemetry: Minimum 24-48 hours
• Prolonged Ambulatory Monitoring: 30-day mobile cardiac telemetry (MCOT)
• or external loop recorder in cryptogenic TIA (detects paroxysmal AF in 10-15%)
• Transthoracic Echocardiogram (TTE) with Bubble Study: Evaluates for intracardiac
• thrombus, patent foramen ovale (PFO), atrial septal aneurysm, valvular vegetations

• 4. LABORATORY EVALUATION
• CBC (platelets), PT/INR, aPTT, Fasting Lipid Panel (LDL), HbA1c, CMP, Troponin
• Neurovascular Imaging & Carotid Revascularization

Carotid artery atherosclerosis is responsible for approximately 15% to 20% of ischemic strokes. When an atheroma at the carotid bifurcation ulcerates or narrows the lumen, it generates recurrent artery-to-artery thromboemboli.

Symptomatic Severe Internal Carotid Artery Stenosis (70% to 99% by NASCET criteria) :

Urgent Carotid Endarterectomy (CEA) is strongly indicated within 14 days of the index ischemic event (optimally within 48 to 72 hours once clinical and neurological stability is established).

Evidence : Landmark trials (NASCET, ECST) proved that CEA reduces the 5-year absolute stroke risk by >16% (number needed to treat [NNT] ~6).

Carotid Artery Stenting (CAS) : An effective alternative for patients with hostile neck anatomy (prior radical neck dissection, radiation arteritis, tracheostomy), severe tandem stenosis, or prohibitive cardiopulmonary surgical risk.

Symptomatic Moderate Stenosis (50% to 69%) :

CEA provides moderate benefit (NNT ~15-20), particularly in men, patients aged ≥75 years, and those with hemispheric (rather than retinal) symptoms; surgery should also be performed within 14 days.

Mild Stenosis (<50%) or Complete Occlusion (100%) :

Surgical revascularization is NOT indicated . Complete occlusion carries a high surgical complication risk with zero downstream flow to preserve; patients are managed with intensive medical therapy.

Cardiac Telemetry & Occult Atrial Fibrillation

Cardioembolism accounts for up to 25% of ischemic strokes and TIAs, with Atrial Fibrillation (AF) representing the predominant cause. Because paroxysmal AF is frequently asymptomatic and intermittent, a normal 12-lead ECG or brief 24-hour telemetry strip does not exclude the diagnosis. Landmark randomized trials ( CRYSTAL AF , EMBRACE ) demonstrated that extended ambulatory cardiac monitoring with a 30-day mobile cardiac outpatient telemetry (MCOT) or an implantable loop recorder detects occult paroxysmal atrial fibrillation in 10% to 15% of patients with cryptogenic TIA/stroke , fundamentally shifting management from antiplatelet therapy to oral anticoagulation.

Secondary Stroke Prevention Pharmacotherapy

Secondary prevention must be initiated immediately upon confirmation of TIA or minor stroke. EVIDENCE-BASED SECONDARY PREVENTION REGIMEN

• ┌─────────────────────────────────────────────────────────────┐
• │ 1. DUAL ANTIPLATELET THERAPY (DAPT) - THE 21-DAY RULE │
• │ • INDICATION: High-risk TIA (ABCD2 ≥ 4) or minor stroke │
• │ (NIHSS ≤ 3) presenting within 24 hours of onset │
• │ • REGIMEN: Aspirin 81 mg daily PLUS Clopidogrel 75 mg │
• │ daily (with 300-600 mg clopidogrel loading dose) │
• │ • DURATION: EXACTLY 21 DAYS (CHANCE & POINT trials) │
• │ • DAY 22 ONWARD: Transition to single antiplatelet │
• │ monotherapy lifelong (Aspirin 81 mg or Clopidogrel) │
• └──────────────────────────────┬──────────────────────────────┘
• ▼
• ┌─────────────────────────────────────────────────────────────┐
• │ 2. HIGH-INTENSITY STATIN THERAPY │
• │ • INDICATION: All atherosclerotic non-cardioembolic TIA │
• │ • REGIMEN: Atorvastatin 80 mg daily (or Rosuvastatin 40) │
• │ • TARGET: LDL-C reduction ≥50% AND absolute LDL < 70 mg/dL│
• │ (SPARCL trial); add Ezetimibe 10 mg if target unmet │
• └──────────────────────────────┬──────────────────────────────┘
• ▼
• ┌─────────────────────────────────────────────────────────────┐
• │ 3. BLOOD PRESSURE OPTIMIZATION │
• │ • ACUTE PHASE (first 24-48h): Permissive hypertension; │
• │ withhold antihypertensives unless BP > 220/120 mmHg │
• │ • LONG-TERM TARGET: < 130/80 mmHg (PROGRESS trial) │
• │ • PREFERRED AGENTS: ACE inhibitors, ARBs, Thiazide-like │
• │ diuretics (Perindopril + Indapamide) │
• └──────────────────────────────┬──────────────────────────────┘
• ▼
• ┌─────────────────────────────────────────────────────────────┐
• │ 4. ORAL ANTICOAGULATION (IF ATRIAL FIBRILLATION DETECTED) │
• │ • FIRST-LINE: DOACs (Apixaban 5 mg BID, Rivaroxaban │
• │ 20 mg daily, Dabigatran 150 mg BID, Edoxaban 60 mg) │
• │ • DOACs preferred over Warfarin (>50% reduction in ICH) │
• │ • DISCONTINUE antiplatelets when starting DOAC │
• └─────────────────────────────────────────────────────────────┘
• 1. Dual Antiplatelet Therapy (DAPT): The CHANCE and POINT Landmark Evidence

The Clinical Paradigm :

In patients with high-risk TIA ( ABCD2 score ≥ 4 ) or acute minor ischemic stroke ( NIHSS score ≤ 3 ) who present within 24 hours of symptom onset, combining two antiplatelet agents with complementary mechanisms provides superior inhibition of platelet aggregation during the peak window of stroke recurrence.

Landmark Clinical Trials :

CHANCE Trial (NEJM 2013) : Conducted in China with 5,170 patients randomized to Aspirin + Clopidogrel for 21 days versus Aspirin monotherapy. DAPT significantly reduced 90-day recurrent stroke (8.2% vs. 11.7%; Hazard Ratio 0.68, p<0.001)—a 32% relative risk reduction—with no increase in major hemorrhagic events.

POINT Trial (NEJM 2018) : International multicenter trial with 4,881 patients randomized to Aspirin + Clopidogrel for 90 days versus Aspirin monotherapy. DAPT significantly reduced major ischemic events (5.0% vs. 6.5%; HR 0.75). However, major hemorrhage was significantly higher in the DAPT group (0.9% vs. 0.4%; HR 2.32). Crucially, secondary time-to-event analysis revealed that the ischemic benefit was concentrated entirely within the first 21 days , whereas the risk of major hemorrhage continued to accumulate beyond day 21.

CRITICAL BOARD RULE: DAPT DURATION IS EXACTLY 21 DAYS :

DAPT with Aspirin 81 mg daily PLUS Clopidogrel 75 mg daily (initiated with an oral loading dose of 300 to 600 mg clopidogrel) must be continued for 21 days . At day 21, clopidogrel is stopped, and the patient is transitioned to lifelong single antiplatelet monotherapy (Aspirin 81 mg daily, Clopidogrel 75 mg daily, or Aspirin 25 mg / Extended-Release Dipyridamole 200 mg BID). Continuing DAPT beyond 21 days confers zero additional ischemic benefit while significantly elevating the risk of life-threatening intracranial and gastrointestinal hemorrhage.

2. High-Intensity Statin Therapy

All patients with non-cardioembolic TIA or ischemic stroke of atherosclerotic origin must be started immediately on high-intensity statin therapy, regardless of their baseline cholesterol level.

Regimen : Atorvastatin 80 mg PO daily (or Rosuvastatin 20 to 40 mg daily).

Evidence & Targets : The landmark SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) proved that high-dose atorvastatin reduced the 5-year absolute risk of recurrent stroke by 16%. The therapeutic target is an LDL-C reduction of ≥50% from baseline and an absolute LDL-C level <70 mg/dL (or <55 mg/dL in patients with multiple major cardiovascular events). If the target is not achieved on maximally tolerated statin therapy, add Ezetimibe 10 mg daily .

3. Blood Pressure Optimization

Acute Phase (First 24 to 48 Hours) : In the acute post-TIA period, autoregulation of cerebral blood flow in the ischemic penumbra is impaired. Rapid, aggressive blood pressure lowering can induce penumbral hypoperfusion and convert viable tissue into completed infarction. Antihypertensive therapy is withheld unless blood pressure exceeds 220/120 mmHg or there are severe end-organ emergencies (acute coronary syndrome, aortic dissection, hypertensive encephalopathy).

Chronic Maintenance Phase : Once stability is confirmed, long-term blood pressure control is the single most powerful intervention to prevent recurrent stroke. The goal is <130/80 mmHg . Preferred regimens include an ACE inhibitor or ARB paired with a thiazide-like diuretic (e.g., perindopril and indapamide, proven in the PROGRESS trial ).

4. Oral Anticoagulation for Cardioembolic TIA

If cardiac telemetry, Holter monitoring, or echocardiography reveals atrial fibrillation, atrial flutter, or intracardiac thrombus , antiplatelet therapy is discontinued and replaced by therapeutic oral anticoagulation.

Direct Oral Anticoagulants (DOACs) — Apixaban (5 mg BID), Rivaroxaban (20 mg daily), Dabigatran (150 mg BID), or Edoxaban (60 mg daily)—are the preferred first-line agents over warfarin. DOACs provide equivalent or superior stroke prevention with a >50% reduction in catastrophic intracranial hemorrhage .

Warfarin (target INR 2.0 to 3.0) is strictly reserved for patients with mechanical prosthetic heart valves or moderate-to-severe rheumatic mitral stenosis.

Antiplatelet Cessation : In patients initiated on oral anticoagulants for atrial fibrillation, concurrent antiplatelet therapy must be discontinued unless the patient has had a recent percutaneous coronary intervention (within 1-12 months), because combining antiplatelets with anticoagulants doubles the risk of major bleeding without lowering ischemic stroke rates.

Loading diagram... Comprehensive TIA Triage, Scoring & Management Pathway